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The main terminology 
used to describe heart fail-
ure (HF) is based on the 
measurement of the left 
ventricular ejection frac-
tion (LVEF), and current 
guidelines divide patients 
into three subgroups: heart 
failure with preserved ejec-
tion fraction (HFpEF) if LVEF > 50%, heart failure 
with mid-range ejection fraction (HFmrEF) if LVEF 
is between 40% and 49% and heart failure with re-
duced ejection fraction (HFrEF) if LVEF is < 40% 
[1]. LVEF has been the main selection criteria for 
most clinical trials during the past three decades, 
however, improved morbidity and mortality rates 
have only been shown in patients with HFrEF. 
On the contrary, despite a long history of clini-
cal trials on HFpEF, there has been no proof of any 
single drug which improves survival rates in this 
subset of patients. There is a common understand-
ing that this lack of success could be linked to the 
fact that HFpEF is comprised of a wide variety of 
unrelated pathologies. 
In this issue of ‘Cardiology Journal’, Junbo Ge 
proposes a new classification for HFpEF into five 
categories based on their etiology and pathophysi-
ology: 1) vascular related HFpEF, 2) cardiomyopa-
thy-related HFpEF, 3) right-heart and pulmonary-
related HFpEF, 4) valvular and rhythm related 
HFpEF, and 5) extracardiac-disease related HFpEF 
[2]. This new categorization could potentially allow 
more targeted clinical trials, and hopefully achieve 
some benefit in certain subgroups. 
However, the main problem may not be 
HFpEF itself, but by the way HF  is diagnosed and 
classified. The concept of LVEF, which is defined 
by dividing the stroke volume by the end-diastolic 
volume, was developed in the 1960s [3], and has 
become a cornerstone in cardiology since then. 
Nonetheless, HF patients, disease phenotypes 
and technology have evolved significantly since 
then, and nowadays the information provided by 
the LVEF is inadequate or insufficient in many 
situations.
There are various setbacks to two-dimensional 
echocardiography measured LVEF [4]. First and 
foremost, there is a 10% of interobserver vari-
ability [5], which may lead to the same patient 
falling into different categories depending on the 
echocardiographer who reads the study, and it var-
ies depending on the imaging method used and on 
the cut-planes. Secondly, it is widely influenced 
by geometry, which is particularly important in is-
chemic cardiomyopathy, and by ventricular loading, 
especially afterload. Moreover, it does not take into 
account the complexity of myocardial mechanics 
or the speed of contraction, and its assessment 
in patients with mechanical dyssynchrony, which 
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is still under debate. Last, but not least, ejection 
fraction (EF) has proven prognostic significance 
in patients with EF < 40%, but in patients with 
EF > 40% there is no correlation between higher 
EF and better outcomes [6]. 
Taking into account the abovementioned 
statements, certain doubts arise regarding the 
suitability of LVEF as the best method to classify 
HF patients. What if LVEF were too simple a clas-
sification for such a complex disease?
Changing the current classification would 
probably shake the foundations of HF as we know 
it today, since most clinical trials that have shown 
benefit were based on this concept. However, hav-
ing said this, there is clearly room for improvement.
Left ventricular mechanics (as measured by 
two-dimensional speckle-tracking echocardiog-
raphy), three-dimensional echocardiography or 
cardiac magnetic resonance (CMR) all allow for 
an improved assessment of myocardial function. 
Global longitudinal strain has been shown to 
correlate with prognosis in all patients with HF, 
regardless their LVEF, and provides the greatest 
incremental information when the LVEF is rela-
tively preserved and regional wall motion scores 
are normal [7]. On the other hand, CMR plays an 
important role in the diagnosis of many HFpEF 
pathologies, such as hypertrophic cardiomyopathy 
or cardiac amyloidosis, and its role on prognosis in 
many others has already been stablished [8]. 
On top of that, CMR is the most reliable 
method to identify inflammation, which is the 
main histopathological substrate of many different 
causes of HFpEF. Sustained inflammation leads to 
interstitial fibrosis and myocardial hypertrophy, 
that cause impaired left ventricular relaxation and 
coronary microvascular dysfunction [9].
The point of view herein, is that it is not only 
necessary to identify the etiology of HF, as Junbo 
Ge [2] proposes in his article, but also to create 
new diagnostic and prognostic scores that include 
all the aforementioned tools, allowing a better clas-
sification of HF patients. It is highly probable that 
treatments based on integrating all this information 
will provide better clinical results than those based 
solely on LVEF. Recent drugs that have failed to 
prove benefit in HFpEF may have a role in a subset 
of patients with reduced left ventricular mechanics 
or active inflammation. 
In conclusion, it seems that the actual concept 
of LVEF is set in stone, but perhaps it is time to 
think out of the box and rewrite the basics of heart 
failure.
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